Delivery Order SPE2DR25D2018-SPE2DR26FZ0E9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,558.40 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 25, 2025, with completion by November 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $9,468.86 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count packaging) on December 10, 2025, with completion scheduled for December 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a delivery order valued at $13,173.98 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract type. This non-set-aside competitive award was executed on December 1, 2025, with an ultimate completion date of December 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a delivery order valued at $5,137.84 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) on October 17, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price, competitively awarded delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $20,525.18 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on November 26, 2025, with an ultimate completion date of November 28, 2025. This non-set-aside, firm fixed-price delivery order is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $10,130.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging) on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.86 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $15,558.30 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 24, 2025, with completion scheduled for September 25, 2025. This firm fixed price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $10,969.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was placed under no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid...
- The Defense Logistics Agency awarded a $6,223.32 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for RINVOQ ER 15 mg tablets in quantities of 30 units. The contract, which is non-set-aside and competitively awarded, carries a firm fixed price structure with performance to be completed by August 1, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other...
- SPE2DR25D2018Indefinite Delivery Contract
- SPE2DR25D2018-SPE2DR26FZ0E9Delivery Order
The Defense Logistics Agency awarded a $3,279.20 delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count unit of use packaging). This is a firm fixed-price, non-set-aside competitive award with a completion date of December 12, 2025, to be performed at the contractor's Conshohocken, Pennsylvania location. RINVOQ (upadacitinib) is a Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis and other inflammatory conditions, representing a specialty pharmaceutical requirement within the military healthcare supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical support vehicle enables the contractor to supply a broad range of brand-name and generic medications, specialty drugs, vaccines, and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated consistent capability to meet federal procurement requirements through open competition and serves as a critical vendor for Defense Health Agency medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 12/10/25 |